Amzak Capital Management
980 N Federal Hwy Suite 315, Boca Raton, FL, 33432, United States
Overview
Amzak Capital Management is the private investment firm of the Kazma family. Originally from Canada but based in the U.S. since 1979, the Kazma’s got their start in the cable television industry. Under the leadership of Gerry and his son Mike, the Kazma’s developed and operated cable systems in Canada and the U.S. until 1992, when they entered the Latin American markets, with operations in Aruba, Venezuela, Trinidad & Tobago and Martinique. In 1997, they built and operated Amnet, Central America’s largest cable television / triple play company, which was sold to Millicom International Cellular S.A. in 2008. Over the past ten years, Amzak has transitioned from a family business primarily focused on the cable industry into an institutional investment manager with an investment perspective across a broad range of industries and strategies. Today, Amzak focuses on four major areas: middle market, fixed income, real estate and healthcare. To a lesser extent, the firm also invests in public equity and, very selectively, alternative investments. These investments tend to be either opportunistic or complementary to one of its four investment groups. Amzak’s current portfolio is concentrated in the U.S., South America, Central America and the Caribbean.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Venture Capital
Investment portfolio
- KEW Group
Participated · Series B · Jan 2015
KEW Group provides genomic profiling and evidence-based clinical intelligence to help oncologists design individualized cancer treatments. Its CancerPlex test analyzes over four hundred cancer genes, detects actionable alterations for targeted therapies, and requires smaller tumor samples than many next-generation sequencing tests. The company also offers KEW Therapeutic Pathways and aims to couple patient-specific genomic data with clinical knowledge to inform treatment decisions and potential clinical trial participation. KEW plans to commercialize CancerPlex and KEW Therapeutic Pathways, expand partnership activities with Cardinal Health, and deploy the KEW Oncology Network. The company focuses on serving community oncology practices, noting that roughly 80 percent of U.S. cancer patients are treated in the community setting. KEW is privately held and recently completed a $16.8 million Series B to support these efforts. KEW Group offers genomics-based diagnostic services to inform treatment decisions for community oncologists, notably its CancerPlex gene-testing panel. The company provides KEW MDx tumor genomic testing and KEW TPx Therapeutic Pathways that integrate genomic information into care decisions. KEW says it serves community oncology practices across the U.S. and internationally and is working with seven oncology practices in six states to refine pathways for seven cancer types. The company participates with practices involved in a Center for Medicare and Medicaid Innovation grant testing a Community Oncology Medical Home model. KEW launched CancerPlex as its first product offering to expand access to multiplex, next-generation sequencing for tumor profiling. Management states the recently closed financing provides critical capital to build and expand the reach of its offerings to community oncologists.
Team
No current team members are available.